# A Varegacestat Hepatic Impairment Study

> **NCT06841315** · PHASE1 · COMPLETED · sponsor: **Immunome, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Healthy Volunteer
- Hepatic Impairment (HI)

## Interventions

- **DRUG:** varegacestat

## Key facts

- **NCT ID:** NCT06841315
- **Lead sponsor:** Immunome, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-07
- **Primary completion:** 2025-11-05
- **Final completion:** 2026-03-06
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06841315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06841315, "A Varegacestat Hepatic Impairment Study". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06841315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*